Lido Advisors
RIGL icon

Lido Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Lido Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,911
Closed -$206K – 1045
2022
Q1 		$206K Buy
6,911
+486
+8% +$13.2K ﹤0.01% 945
2021
Q4 		$170K Sell
6,425
-4,329
-40% -$131K ﹤0.01% 968
2021
Q3 		$390K Buy
10,754
+1,647
+18% +$64.8K 0.01% 672
2021
Q2 		$395K Buy
9,107
+2,326
+34% +$87.8K 0.01% 613
2021
Q1 		$232K Sell
6,781
-6,694
-50% -$265K ﹤0.01% 753
2020
Q4 		$471K Buy
13,475
+6,329
+89% +$183K 0.01% 494
2020
Q3 		$171K Buy
7,146
+1,382
+24% +$33.9K ﹤0.01% 599
2020
Q2 		$105K Sell
5,764
-155
-3% -$2.79K ﹤0.01% 576
2020
Q1 		$92K Buy
5,919
+626
+12% +$13.3K ﹤0.01% 559
2019
Q4 		$113K Sell
5,293
-114
-2% -$2.35K ﹤0.01% 637
2019
Q3 		$101K Sell
5,407
-8,943
-62% -$185K 0.01% 565
2019
Q2 		$374K Buy
14,350
+1,383
+11% +$31.2K 0.02% 371
2019
Q1 		$333K Buy
12,967
+1,655
+15% +$37.8K 0.02% 365
2018
Q4 		$260K Buy
11,312
+1,852
+20% +$52.3K 0.03% 344
2018
Q3 		$303K Buy
9,460
+1,397
+17% +$41.9K 0.03% 333
2018
Q2 		$228K Buy
8,063
+2,533
+46% +$90.1K 0.03% 368
2018
Q1 		$195K Buy
+5,530
New +$221K 0.03% 368

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lido Advisors's RIGL Position: Q2 2022 in Review

Lido Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q2 2022, closing a stake of 6,911 shares — an estimated $206K sold.

Lido Advisors first reported a position in RIGL in Q1 2018 and held it in 17 quarters. The position peaked at $471K in Q4 2020. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2022.

  • Lido Advisors reported no remaining Rigel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Lido Advisors sold 6,911 Rigel Pharmaceuticals shares in Q2 2022, an estimated $206K.
  • Lido Advisors first reported a position in Rigel Pharmaceuticals in Q1 2018 and held it in 17 quarters.
  • Lido Advisors's Rigel Pharmaceuticals position peaked at $471K in Q4 2020.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2022.

Based on Lido Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.